- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00189020
Effect of Two Versus Three Pneumococcal Conjugate Vaccinations (MNOES)
Effect of 2 Versus 3 Pneumococcal Conjugate Vaccinations Prevnar on Nasopharyngeal Carriage, Transmission and Herd-immunity;a Randomized, Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Two(2 and 4 months) and three vaccinations (2,4 and 11 months) with 7-valent pneumococcal conjugate vaccine Prevnar in infants are presumed to provide about 90% protection against invasive pneumococcal disease (IPD) for vaccine type pneumococci, at least until 18-24 months of age. Licensure of the vaccine however is based on studies with 3 vaccinations before 6 months and a booster vaccination half a year later (3+1 scheme). Cost-effectiveness in national infant vaccination programs (NIPs)is much improved by high herd-immunity effects,as observed in the USA after licensure of Prevnar in 2000, both for IPD and AOM. However, overall pneumococcal carriage reduction (and nasopharyngeal replacement) has not been assessed in studies with reduced doses. With reduced carriage reduction, effects on respiratory tract infections and herd immunity may be significantly less.
The primary aim of the current study is to compare effect of 2-doses (at ages 2 and 4 months) with a 3-doses scheme(2+1, at 2, 4 and 11 months) on nasopharyngeal pneumococcal carriage and replacement and family transmission(sibs and caregivers), in order to allow modelling for herd-immunity.
The secondary aim is to determine the effect of a reduced doses scheme on serum antipneumococcal antibody levels at the age of 12 and 24 months.
A third aim is to determine antipneumococcal antibody levels and memory B-cell development after booster vaccination at 24 months of age, after 2 or 2+1 doses and compare these with a first vaccination at 24 months of age.
Opportunities are the determination of nasopharyngeal colonizing pneumococci in unvaccinated infants in the Netherlands before implementation of Prevnar in the NIP, evaluation of replacing pneumococci in the nasopharynx after vaccinations and analysis of effects on other colonizing bacteria like H.influenzae, M. catarrhalis and S.aureus. Furthermore, the relation between colonizing pneumococci and serotypes causing IPD in the Netherlands can be evaluated.
Methods : 1000 infants and families will be included in a randomized,controlled study with 3 interventions groups
- Prevnar at 2 and 4 months
- Prevnar at 2, 4 and 11 months
- Prevnar at 24 months (controls)
The children will be followed until 2 years of age with nasopharyngeal swabs for bacterial culture before the first vaccination, at 6, 12, 18 and 24 months of age. One sibling and one parent/caregiver will be swabbed when the infant is 12 and 24 months. Blood for antibody determination will be obtained from 80 children of groups 1 and 2, and from 30 children in the control group. Questionnaires on health and respiratory infections and antibiotic prescription for RTI will be obtained.
At 24 months of age, all children of groups 1 and 2 will be offered a booster vaccination. Antibody levels will be measured before and 4 weeks after this vaccination at 2 years of age in a subset of 80 children per group and compared with 80 children who received a first vaccination at 24 months of age.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newborn infants eligible for participation in the national infant vaccination program in the Netherlands
Exclusion Criteria:
exclusion from the national vaccination program because of the presence of
- a medical condition requiring treatment that can interfere with the effect of vaccinations
- known or suspected allergy to components of the pneumococcal conjugate vaccine
- known or suspected immunodeficiency disease
- previous treatment with plasma or immunoglobulins
- previous vaccinations other than hepatitis B vaccinations
- coagulation disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Control group
|
|
Experimental: 2-dose
PCV7 at age 2 and 4 months
|
PCV7 at age 2 and 4 months
Other Names:
PCV7 at age 2, 4 and 11 months
Other Names:
|
Experimental: 2+1-dose
PCV7 at age 2, 4 and 11 months
|
PCV7 at age 2 and 4 months
Other Names:
PCV7 at age 2, 4 and 11 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Nasopharyngeal bacterial (pneumococcal) colonization at 6 weeks, 6, 12, 18 and 24 months in infants and at 12 and 24 months of family members
Time Frame: duration of study, 23 months per subject
|
duration of study, 23 months per subject
|
transmission to family members( sib, caregiver)
Time Frame: at infants age of 12 and 24 months
|
at infants age of 12 and 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
anti-pneumococcal antibody levels at 12 and 24 months of age
Time Frame: 23 months
|
23 months
|
antibody levels and B-memory cells after vaccination at 24 months
Time Frame: 23 months
|
23 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elisabeth A. M. Sanders, MD, PhD, UMC Utrecht
Publications and helpful links
General Publications
- Biesbroek G, Tsivtsivadze E, Sanders EA, Montijn R, Veenhoven RH, Keijser BJ, Bogaert D. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. Am J Respir Crit Care Med. 2014 Dec 1;190(11):1283-92. doi: 10.1164/rccm.201407-1240OC.
- Biesbroek G, Bosch AA, Wang X, Keijser BJ, Veenhoven RH, Sanders EA, Bogaert D. The impact of breastfeeding on nasopharyngeal microbial communities in infants. Am J Respir Crit Care Med. 2014 Aug 1;190(3):298-308. doi: 10.1164/rccm.201401-0073OC.
- Biesbroek G, Wang X, Keijser BJ, Eijkemans RM, Trzcinski K, Rots NY, Veenhoven RH, Sanders EA, Bogaert D. Seven-valent pneumococcal conjugate vaccine and nasopharyngeal microbiota in healthy children. Emerg Infect Dis. 2014 Feb;20(2):201-10. doi: 10.3201/eid2002.131220.
- van Westen E, Rodenburg GD, van Gils EJ, Tcherniaeva I, Berbers GA, Cowell L, Goldblatt D, Rots NY, van den Dobbelsteen GP, Sanders EA. Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose. Vaccine. 2013 Dec 2;31(49):5834-42. doi: 10.1016/j.vaccine.2013.09.073. Epub 2013 Oct 10.
- Rodenburg GD, van Gils EJ, Veenhoven RH, Bogaert D, van den Dobbelsteen GP, Berbers GA, Sanders EA. Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae. J Pediatr. 2011 Dec;159(6):965-70.e1. doi: 10.1016/j.jpeds.2011.06.011. Epub 2011 Aug 2.
- van Gils EJ, Hak E, Veenhoven RH, Rodenburg GD, Bogaert D, Bruin JP, van Alphen L, Sanders EA. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One. 2011;6(6):e20229. doi: 10.1371/journal.pone.0020229. Epub 2011 Jun 10.
- van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Keijzers WC, Bogaert D, Trzcinski K, Bruin JP, van Alphen L, van der Ende A, Sanders EA. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA. 2010 Sep 8;304(10):1099-106. doi: 10.1001/jama.2010.1290.
- van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP, Bruin JP, van Alphen L, Sanders EA. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009 Jul 8;302(2):159-67. doi: 10.1001/jama.2009.975.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Streptococcal Infections
- Gram-Positive Bacterial Infections
- Pneumonia, Bacterial
- Pneumococcal Infections
- Pneumonia, Pneumococcal
- Physiological Effects of Drugs
- Immunologic Factors
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- MINOES 01, STEG R05 008
- ISRCTN (Registry Identifier: ISRCTN11460478)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Streptococcus Pneumoniae Infection
-
Universidad de la SabanaRecruitingCommunity-acquired Pneumonia | Streptococcus Pneumoniae Infection | Streptococcus Pneumoniae Pneumonia | Streptococcus Pneumoniae Infection InvasiveColombia
-
PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedStreptococcus Pneumoniae InfectionsChina
-
University of OxfordPfizerUnknownStreptococcal Pneumonia | Streptococcus Pneumoniae Infection | Streptococcus Pneumoniae, Invasive DiseaseUnited Kingdom
-
London School of Hygiene and Tropical MedicineUniversity College, London; Bill and Melinda Gates Foundation; Wellcome Trust; KEMRI-Wellcome... and other collaboratorsActive, not recruitingPneumococcal Infection | Streptococcus Pneumoniae Infection | Invasive Pneumococcal Disease, Protection AgainstKenya
-
Radboud University Medical CenterCompletedStreptococcus Pneumoniae InfectionNetherlands
-
Centre Hospitalier Universitaire de NīmesRecruitingStreptococcus Pneumoniae InfectionFrance
-
Merck Sharp & Dohme LLCCompletedPneumococcal Infections | Streptococcus Pneumoniae Infection
-
University of Colorado, DenverPfizerCompletedCommunity-acquired Pneumonia | Streptococcus Pneumoniae InfectionGuatemala
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); University of Calgary; Alberta... and other collaboratorsCompletedStreptococcus Pneumoniae Infection | Invasive Pneumococcal Disease, Protection AgainstCanada
Clinical Trials on PCV7
-
Sheba Medical CenterUnited States Agency for International Development (USAID); Maccabi Healthcare... and other collaboratorsUnknownStreptococcus PneumoniaeIsrael
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI)CompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Kaiser PermanenteCenters for Disease Control and PreventionCompleted
-
Novartis VaccinesCompleted
-
Centers for Disease Control and Prevention, ChinaBeijing Center for Disease Control and Prevention; Beijing Municipal Health...CompletedNasopharyngeal Diseases | Streptococcal Pneumonia | Vaccination Adverse EventChina
-
PfizerCompletedNeisseria Meningitidis (Bacterial Meningitis) | Invasive Pneumococcal Disease (IPD)Germany
-
State University of New York at BuffaloCompletedSecondary-progressive Multiple SclerosisUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedLymphoma | Small Intestine Cancer | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Peking University People's HospitalPeking University First Hospital; Jiangsu Province Geriatric InstituteRecruitingDiabetes Mellitus, Type 2 | Severe Insulin Deficient DiabetesChina